Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer
Stopped PI discretion based on low accrual
Conditions
- Metastatic Pancreatic Adenocarcinoma
Interventions
- DRUG: Regorafenib
- DRUG: Gemcitabine Hydrochloride
Sponsor
Case Comprehensive Cancer Center
Collaborators